A Step Towards Personalized Medicine: PET-PSMA Imaging in Prostate Cancer VL

OSPREY and CONDOR Trials - Evaluating F-18 DCFPyL PSMA Imaging for Prostate Cancer - Michael J. Morris

Details
A Step Towards Personalized Medicine: PSMA-PET Imaging in Prostate Cancer F-18 DCFPyL PSMA Imaging for Prostate Cancer: OSPREY and CONDOR. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section...

The Biology of Prostate Cancer Metastasis and What PSMA Imaging Is Teaching Us: Presentation and Discussion - Kenneth J. Pienta

Details
A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer. The Biology of Prostate Cancer Metastasis and What PSMA Imaging is Teaching Us Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Presenter: Kenneth J. Pienta, MD, is the Donald S. Coffey Professor at the Brady Urological Institute at Jo...

Diagnostic Molecular Imaging for Prostate Cancer in the United States: A Focus on Lesion Localization and Distribution Using 18F-DCFPyL PET/CT at Biochemical Recurrence Lecture & Discussion - Andrei H...

Details
A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer. Diagnostic Molecular Imaging for Prostate Cancer in the United States - Andrei H Iagaru Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine, Chief, Division of Nuclear...

Implications of PSMA PET Imaging for Prostate Cancer Presentation & Discussion - Oliver Sartor

Details
A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer Implications of PSMA PET Imaging for Prostate Cancer Presentation & Discussion - Oliver Sartor Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Presenter: A. Oliver Sartor, MD Professor of Medicine and Medical Director, Tulane Cancer Ce...

Applying Artificial Intelligence (AI) to PSMA-targeted PET Imaging Agent 18F-DCFPyL in Prostate Cancer: Lecture & Discussion- Matthew Rettig

Details
A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer. Applying Artificial Intelligence (AI) to PSMA-targeting PET Imaging Agent 18F-DCFPyL (PYL) in Prostate Cancer: Lecture & Discussion. - Matthew Rettig Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Presenter: Matthew Rettig, MD. is Pr...